Loading...
Market
First region to approve Merck's clesrovimab for RSV prevention in infants?
2
Resolution / Starting Odds
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%
Regulatory announcements from regional health authorities
Story
Merck's Clesrovimab Shows 60.4% Efficacy in Preventing RSV in Infants
Oct 17, 2024, 10:02 PM
Merck's investigational monoclonal antibody, clesrovimab (MK-1654), has demonstrated significant efficacy in reducing the incidence of respiratory syncytial virus (RSV) disease and hospitalization in healthy preterm and full-term infants. The experimental therapy showed a 60.4% effectiveness in reducing RSV infections in infants, according to data released by Merck. This positive outcome paves the way for potential approval of clesrovimab as a preventative treatment for RSV in infants.
View original story
Similar markets
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
More than 30 countries • 25%
USA • 25%
EU • 25%
Canada • 25%
Other • 25%
Canada • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
Yes • 50%
No • 50%
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%
European Union • 25%
Canada • 25%
Japan • 25%
Australia • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Europe • 25%
Asia • 25%
South America • 25%
Other • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%